<p>Immuneering Corporation（纳斯达克代码：IMRX - 获取免费报告）内部人士 Brett Matthew Hall 于 1 月 15 日（星期四）购买了该公司 2,298 股股票，交易价格为每股平均 4.57 美元，总价值为 10,501.86 美元。收购后，该内部人士直接持有 376,496 股公司股票，价值为 1,720,586.72 美元。此次交易使其持股增加了 0.61%。该交易已在向 SEC 的备案中披露，相关信息可通过此链接访问。</p>
<h2>Immuneering 股票表现</h2>
<p>在周五的交易时段，纳斯达克：IMRX 下跌 0.06 美元，达到 4.58 美元。该股票的交易量为 1,571,491 股，而其平均交易量为 4,332,983 股。该股票的 50 日简单移动平均为 6.41 美元，200 日简单移动平均为 5.77 美元。Immuneering Corporation 的 12 个月最低价为 1.10 美元，最高价为 10.08 美元。该股票的市值为 2.9573 亿美元，市盈率为-2.57，贝塔值为 0.48。</p>
<p>Immuneering（纳斯达克：IMRX - 获取免费报告）最近于 11 月 12 日（星期三）公布了季度财报。公司报告本季度每股收益（EPS）为-0.38 美元，低于分析师一致预期的-0.37 美元，差距为 0.01 美元。平均而言，股票分析师预计 Immuneering Corporation 在当前财政年度的每股收益将为-1.86 美元。</p>
<h2>对 Immuneering 的对冲基金看法</h2>
<p>一些机构投资者最近买入和卖出了该股票的股份。Jane Street Group LLC 在第一季度以约 32,000 美元的估值购买了 Immuneering 的新头寸。中国环球资产管理有限公司在第三季度以约 35,000 美元的估值购买了 Immuneering 的新头寸。Future Financial Wealth Management LLC 在第三季度以约 35,000 美元的估值购买了 Immuneering 的新头寸。Kingsview Wealth Management LLC 在第二季度以 47,000 美元的估值购买了 Immuneering 的新头寸。最后，Mercer Global Advisors Inc. ADV 在第三季度以 70,000 美元的估值购买了 Immuneering 的新股份。67.65% 的股票由机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>IMRX 成为多份研究报告的主题。Leerink Partners 在 10 月 31 日（星期五）的研究报告中将 Immuneering 的股票评级上调至 “强力买入”。瑞穗证券在 10 月 29 日（星期三）的研究报告中对 Immuneering 设定了 12.00 美元的目标价。HC Wainwright 在 9 月 30 日（星期二）的研究报告中重申了 “买入” 评级，并设定了 11.00 美元的目标价。Wall Street Zen 在 12 月 20 日（星期六）的报告中将 Immuneering 的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重申了 Immuneering 的 “卖出（d-）” 评级。一位投资分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 16.50 美元。</p>
<p><strong>查看我们关于 IMRX 的最新研究报告</strong></p>
<h2>关于 Immuneering</h2>
<p>（获取免费报告）</p>
<p>Immuneering（纳斯达克：IMRX）是一家临床阶段的生物制药公司，利用人工智能和其专有的 RABIT（重新利用和加速生物技术工具）平台设计和优化小分子和肽类疗法。通过分析大规模生物医学数据集，Immuneering 的机器学习算法识别新型药物 - 靶点相互作用，重新利用现有药物框架并加速候选药物的选择。该公司的人工智能驱动方法旨在缩短开发时间并改善在高未满足医疗需求领域的治疗效果。</p>
<p>该公司的主导项目 IRX-2 是一种小分子候选药物，目前正在进行针对疼痛性糖尿病周围神经病的第二阶段临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Immuneering 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>为什么特朗普和马斯克突然关心福特诺克斯</li>
<li>如果您在美国银行账户中存放现金……请立即阅读此信息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1SWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1SWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Immuneering 吗？</h2>
<p>在您考虑 Immuneering 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出顶级分析师正在悄悄向客户推荐的五只股票，以便在更广泛的市场注意到之前购买……而 Immuneering 并不在名单上。</p>
<p>虽然 Immuneering 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

IMRX

<p>Immuneering Corporation（纳斯达克代码：IMRX）的内部人士 Brett Matthew Hall 以每股 4.57 美元的价格购买了 2,298 股，总计 10,501.86 美元，使其持股增加了 0.61%，达到 376,496 股，市值为 1,720,586.72 美元。该交易已向美国证券交易委员会（SEC）披露。该股票下跌 0.06 美元，报 4.58 美元，市值为 2.9573 亿美元。分析师的评级各不相同，其中有一项强烈买入、六项买入和一项卖出，平均目标价为 16.50 美元。Immuneering 是一家专注于人工智能驱动药物开发的临床阶段生物制药公司</p>

<p>Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average price of $4.57 per share, with a total value of $10,501.86. Following the acquisition, the insider directly owned 376,496 shares of the company's stock, valued at $1,720,586.72. The trade was a 0.61% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Immuneering Corporation（纳斯达克代码：IMRX - 获取免费报告）内部人士 Brett Matthew Hall 于 1 月 15 日（星期四）购买了该公司 2,298 股股票，交易价格为每股平均 4.57 美元，总价值为 10,501.86 美元。收购后，该内部人士直接持有 376,496 股公司股票，价值为 1,720,586.72 美元。此次交易使其持股增加了 0.61%。该交易已在向 SEC 的备案中披露，相关信息可通过此链接访问。</p>
</div><h2>Immuneering Stock Performance</h2>
<div class="lb-trans"><h2>Immuneering 股票表现</h2>
</div><p>NASDAQ:IMRX traded down $0.06 during trading hours on Friday, reaching $4.58. The stock had a trading volume of 1,571,491 shares, compared to its average volume of 4,332,983. The stock has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $5.77. Immuneering Corporation has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a market cap of $295.73 million, a P/E ratio of -2.57 and a beta of 0.48.</p>
<div class="lb-trans"><p>在周五的交易时段，纳斯达克：IMRX 下跌 0.06 美元，达到 4.58 美元。该股票的交易量为 1,571,491 股，而其平均交易量为 4,332,983 股。该股票的 50 日简单移动平均为 6.41 美元，200 日简单移动平均为 5.77 美元。Immuneering Corporation 的 12 个月最低价为 1.10 美元，最高价为 10.08 美元。该股票的市值为 2.9573 亿美元，市盈率为-2.57，贝塔值为 0.48。</p>
</div><p>Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, equities analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Immuneering（纳斯达克：IMRX - 获取免费报告）最近于 11 月 12 日（星期三）公布了季度财报。公司报告本季度每股收益（EPS）为-0.38 美元，低于分析师一致预期的-0.37 美元，差距为 0.01 美元。平均而言，股票分析师预计 Immuneering Corporation 在当前财政年度的每股收益将为-1.86 美元。</p>
</div><h2>Hedge Funds Weigh In On Immuneering</h2>
<div class="lb-trans"><h2>对 Immuneering 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Immuneering during the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Future Financial Wealth Managment LLC bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the second quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Immuneering in the third quarter worth $70,000. 67.65% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了该股票的股份。Jane Street Group LLC 在第一季度以约 32,000 美元的估值购买了 Immuneering 的新头寸。中国环球资产管理有限公司在第三季度以约 35,000 美元的估值购买了 Immuneering 的新头寸。Future Financial Wealth Management LLC 在第三季度以约 35,000 美元的估值购买了 Immuneering 的新头寸。Kingsview Wealth Management LLC 在第二季度以 47,000 美元的估值购买了 Immuneering 的新头寸。最后，Mercer Global Advisors Inc. ADV 在第三季度以 70,000 美元的估值购买了 Immuneering 的新股份。67.65% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>IMRX has been the topic of several research reports. Leerink Partnrs upgraded shares of Immuneering to a &#34;strong-buy&#34; rating in a research report on Friday, October 31st. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. HC Wainwright restated a &#34;buy&#34; rating and set a $11.00 price target on shares of Immuneering in a research report on Tuesday, September 30th. Wall Street Zen cut Immuneering from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, December 20th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Immuneering in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $16.50.</p>
<div class="lb-trans"><p>IMRX 成为多份研究报告的主题。Leerink Partners 在 10 月 31 日（星期五）的研究报告中将 Immuneering 的股票评级上调至 “强力买入”。瑞穗证券在 10 月 29 日（星期三）的研究报告中对 Immuneering 设定了 12.00 美元的目标价。HC Wainwright 在 9 月 30 日（星期二）的研究报告中重申了 “买入” 评级，并设定了 11.00 美元的目标价。Wall Street Zen 在 12 月 20 日（星期六）的报告中将 Immuneering 的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 12 月 29 日（星期一）的研究报告中重申了 Immuneering 的 “卖出（d-）” 评级。一位投资分析师对该股票给予了强力买入评级，六位分析师给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 16.50 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on IMRX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 IMRX 的最新研究报告</strong></p>
</div><h2>About Immuneering</h2>
<div class="lb-trans"><h2>关于 Immuneering</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.</p>
<div class="lb-trans"><p>Immuneering（纳斯达克：IMRX）是一家临床阶段的生物制药公司，利用人工智能和其专有的 RABIT（重新利用和加速生物技术工具）平台设计和优化小分子和肽类疗法。通过分析大规模生物医学数据集，Immuneering 的机器学习算法识别新型药物 - 靶点相互作用，重新利用现有药物框架并加速候选药物的选择。该公司的人工智能驱动方法旨在缩短开发时间并改善在高未满足医疗需求领域的治疗效果。</p>
</div><p>The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.</p>
<div class="lb-trans"><p>该公司的主导项目 IRX-2 是一种小分子候选药物，目前正在进行针对疼痛性糖尿病周围神经病的第二阶段临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Immuneering</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Why Trump and Musk suddenly care about Fort Knox</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Immuneering 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护您的财富</li>
<li>为什么特朗普和马斯克突然关心福特诺克斯</li>
<li>如果您在美国银行账户中存放现金……请立即阅读此信息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1SWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=IMRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immuneering Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Immuneering 吗？</h2>
</div><p>Before you consider Immuneering, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Immuneering 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出顶级分析师正在悄悄向客户推荐的五只股票，以便在更广泛的市场注意到之前购买……而 Immuneering 并不在名单上。</p>
</div><p>While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immuneering 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

内幕交易：Immuneering（NASDAQ:IMRX）的内部人士购买了 2,298 股股票